INTRODUCTION AND OBJECTIVES: Prostate cancer (PCa) is the second leading cause of cancer deaths in men. AR signaling is known to play a critical role in androgen responsive prostate cancer cells. Androgen deprivation therapy (ADT) is a standard of care for patients when prostate cancer has spread beyond the prostate. Almost all the prostate cancer (PCa) deaths result from castration resistant prostate cancer (CRPC). With the development of newer anti-androgen Enzalutamide (ENZ) there has been a marked improvement in CRPC. However, almost all patients develop resistance to ENZ in part due to expression of ARv7. Thus, to date, no acceptable treatment options are available for ENZ resistant CRPC. In the present study we evaluated the effects of TET, a derivative of bis-benzyly isoquinoline, Tetrandrine on two enzalutamide resistant prostate cancer cell lines on sensitizing these cells to Enzalutamide. We also evaluated the effects of TET on AR and ARv7 levels.
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METHODS: Enz resistant Prostate cancer cell lines (22rv1 and LNCaP-abl) were used in the present study. Cells were grown in supplemented media and maintained at 370C in a 5%CO2 incubator (as described elsewhere). Where indicated cells were treated with Enzalutamide or TET alone or in combination. Cell viability was measured by crystal violet and MTT assays. Protein levels were measured by Western Blot assays. mRNA expression measured in RTPCR assays.
RESULTS: Treatment with Enz had only a marginal effect on growth and viability of 22rv1 cells. TET inhibited growth and proliferation of enzalutamide resistant prostate cancer cells in both dose and time dependent manner with an IC50 in the range of 5-10uM at 72 hr. However TET treatment did not result in death of RWPE cells, a line of normal prostate cells. Moreover, combination of TET and Enz was more effective than either treatment alone. Treatment with TET resulted in decreased levels of full length AR as well as ARv7 within 24-48h. We also observed that TET treatment was associated with decreased cyclin D1 and increased CDK inhibitors p21 and p27. Over all Tet alone and in combination with Enz promoted cell growth arrest and cell death in ENZ resistant CRPC cells and sensitized these cells to Enz.
CONCLUSIONS: This study shows that TET sensitizes CRPC cells to Enz in part by decreasing protein levels of AR and ARv7. 
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INTRODUCTION AND OBJECTIVES:
The clinical success of new androgen receptor (AR)-targeted therapies in patients with castration-resistant prostate cancer (CRPC) emphasizes the continued importance of the AR signaling axis in the disease. Despite the use of this new generation of therapies, some men with CRPC do not respond and resistance to these therapies typically develops for those that do. Mechanisms attributed to the emergence of this non-responsive CRPC include the expression of splice variants of the AR (AR-SV), mutant forms of the AR, hyperactive AR, and others. The objective of this work is to develop selective androgen receptor degraders (SARDs) that degrade all forms of the AR and provide advanced treatment options to men with CRPC.
METHODS: AR ligand binding, transactivation, fluorescence polarization, nuclear magnetic resonance (NMR), and Western blot assays were performed to screen novel SARDs. Prostate cancer cell line gene expression, proliferation, cell line and patient-derived xenografts (PDX) were performed to evaluate the efficacy of the SARDs. Molecular mechanistic studies were performed to understand the mechanism of action.
RESULTS: This report details a novel series of highly potent SARDs that bind to the AR-LBD and inhibit transactivation at nM concentrations. One of the lead SARDs, UT-155 antagonizes AR with an IC 50 of 78nM in comparison to enzalutamide with an IC 50 of 465nM. In addition to their antagonistic activity, the SARDs degrade full-length, mutant and variant AR in the low mM range and inhibit the proliferation of AR-FL and AR-SV-dependent PCa cells with potencies better than that of the comparators. The SARDs robustly inhibit the growth of the LNCaP androgen-dependent prostate cancer (PCa) xenograft, the 22RV1 CRPC xenograft, and AR-and AR-SV-positive CRPC patient-derived xenografts (PDX). No significant toxicities have been observed in the animal studies that have been performed. NMR analysis as well fluorescence quenching support an interaction between the SARDs and the AR activation function domain (AF-1), making these molecules first-in-class dual-interacting AR antagonists and degraders.
CONCLUSIONS: Novel highly potent SARDs that interact with both AF-1 and LBD of the AR were discovered and characterized as a potential next-generation treatment option for advanced prostate cancer that is resistant to enzalutamide treatment. Clinical development of these compounds is ongoing.
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MP57-04 NOVEL THERAPIES TARGETING ANDROGEN RECEPTOR VARIANTS IN AN IN VITRO MODEL OF CASTRATE RESISTANT PROSTATE CANCER
Joseph A. Baiocco*, Michael Moses, Matthew J. Watson, Raju Chelluri, Bethesda, MD; Jason Gestwicki, San Francisco, CA; Jane Trepel, Len Neckers, Bethesda, MD INTRODUCTION AND OBJECTIVES: VT464 is currently in clinical trials for the treatment of castration-resistant prostate cancer (CRPC). Interestingly, VT464 displays dual properties: it decreases androgen synthesis by inhibiting CYP17A1 and may also block AR function by binding to the ligand-binding domain (LBD) of full-length androgen receptor (ARFL). However, expression of AR variants (e.g. ARv7) lacking a LBD is a common occurrence in CRPC. Thus, ARv7 may be insensitive to direct inhibition by VT464 and other targeted agents may be necessary to blunt ARv7 expression and ARv7 regulated pathways for efficacy in CRPC. ARv7 is stabilized by heat shock proteins (Hsp) 40 and Hsp70, which bind the AR and ARv7 N-terminal domain to prevent aggregation. Our novel compounds C86 and JG98 are inhibitors of Hsp40 and Hsp70, respectively. As such, we hypothesized that inhibition of the Hsp40/70 axis would lead to decreased CRPC cell viability and altered AR/ARv7 expression, which could be amplified in combination with VT464. Additionally, ARv7 leads to changes in cell metabolism such that cells are more dependent on glutaminolysis and fatty acid synthesis. Thus, we also hypothesized that e764 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 
